The Cancer Program

Patient Portal

Inspirational Healing Stories

Real Patients. Real Healing. Real Hope.

Infuze MD has helped thousands of patients throughout the United States manage and/or cure chronic illnesses like cancer, mold exposure, chronic fatigue, long COVID, Lyme disease, and autoimmune issues, among others.

Here we present a series of cases where our patients have been successful, with our care and protocols, in positively managing their conditions. Each case has a real patient behind it; however, we have changed the names in order to respect our patients’ anonymity.

We hope these stories inspire you and give you hope! We’re here to help.

Colorectal Cancer with Brain Metastasis

Sex: Female | Age: 44

Triple-Negative Breast Cancer

Sex: Female | Age: 43

Breast Cancer with Lymph Node Involvement

Sex: Female | Age: 39

Colorectal Cancer

Sex: Female | Age: 55

Metastatic Colorectal Cancer

Sex: Male | Age: 42

Stage 1 Breast Cancer

Sex: Female | Age: 44

Stage 4 Stomach Cancer

Sex: Female | Age: 45

Mold Exposure, Heavy Metal Toxicity, and Autoimmune Issues

Sex: Female | Age: 38

Metastatic Lung Cancer

Sex: Male | Age: 74

Metastatic Pancreatic Cancer

Sex: Male | Age: 55

Papillary Thyroid Cancer with Lymph Node Involvement

Sex: Female | Age: 50

If you’d like more information on how we can help you, please don’t

hesitate to reach out to us!

Contact Us
Scroll to Top

Linda: 44-year-old with colorectal cancer with brain metastasis

Diagnosis

Linda, a 44-year-old woman, was diagnosed with adenocarcinoma of the rectum with brain metastasis in 2023. She underwent chemotherapy and radiation, leading her body to deteriorate after the harsh treatments. In addition, after we performed a MycoTOX test, we found out that she had a high concentration of mycotoxins in her body. These mycotoxins (toxic compounds that are naturally produced by certain types of molds) can contribute to cancer occurrence and recurrence, which is why it’s important to address them by detoxifying the body.

Treatment

Linda did an initial 12-day program over the course of 6 weeks,
which included:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Intratumoral injections
  • Non-invasive detox therapies
  • Repurposed medications
Tests
MycoTOX
profile
Guardant Reveal ctDNA test
Outcome

Linda is currently in remission. Both her most recent circulating tumor DNA (ctDNA) test and CT of abdomen came back negative.

Rose: 43-year-old with triple-negative breast cancer

Diagnosis

Rose is a 43-year-old woman who was diagnosed with triple-negative (ER-/PR-/HER2-) infiltrating ductal carcinoma, stage 2, in 2024. This is one of the hardest types of breast cancer to treat. She was prescribed chemotherapy and immunotherapy by her diagnosing physician. Her Ki-67 score was 76%, which indicates that cancer cells are reproducing rapidly, and the tumor is more likely to be aggressive and spread very quickly. Her initial Signatera test showed positive results for ctDNA. A MycoTOX profile was performed to rule out any mold exposure.

Treatment

Rose did our 20-day program followed by low-dose chemotherapy. The program included:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Hyperthermia
  • Intratumoral injections
  • Repurposed medications
Tests
Initial Signatera test
Most recent Signatera test
Outcome

Rose is currently in remission. Her most recent ctDNA came back negative.

Megan: 39-year-old with breast cancer with lymph node involvement

Diagnosis

Megan is a 39-year-old woman. She was diagnosed with stage 2 HER-2-positive invasive ductal carcinoma in 2025. Invasive ductal carcinoma is the most common type of breast cancer. Her diagnosing physician recommended chemotherapy, a mastectomy, and radiation. She came to us looking to reduce chemotherapy side effects and to strengthen her immune system.

Treatment

Megan has done 30 days of treatment at Infuze MD. Her protocol includes:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Hyperthermia
  • Intratumoral injections
  • Non-invasive detox therapies
  • Repurposed medications
Tests
Initial Natera test
Latest Natera test
Outcome

Megan is currently undergoing treatment. Her initial Natera test showed a mean of 76.44 tumor molecules per mL. Currently, her Natera test shows a mean of 20.26 tumor molecules per mL.

Amanda: 55-year-old with colorectal cancer

Diagnosis

Amanda is a 55-year-old woman who was diagnosed with rectal cancer in March of 2025 after a routine colonoscopy showed polyps and a later biopsy confirmed adenocarcinoma. She came to us wanting to avoid any conventional treatments and wanted to take a completely natural route to address her diagnosis with a whole body approach and to build immunity.

Treatment

Amanda did our 20-day program with treatments that included:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Hyperthermia
  • Repurposed medications
  • Non-invasive detox therapies
Tests
Natera Signatera
Outcome

Amanda is currently in remission as her most recent Signatera test showed a negative result for ctDNA.

Peter: 42-year-old with metastatic colorectal cancer

Diagnosis

Peter is a 42-year-old man diagnosed with rectal adenocarcinoma with metastasis to the bones and abdomen in February of 2023. He was receiving palliative chemotherapy when he came to see us in January of 2025 and was in rough shape. He had previously had surgery, chemotherapy, and radiation. His MSK-IMPACT® (Integrated Mutation Profiling of Actionable Cancer Targets), used to detect mutations and other critical changes in the genes of both rare and common cancers, showed a mutation in the TP53 gene.

Treatment

Treatment

Peter was recommended our 20-day treatment program along with 2 rounds of photo-thermal ablation with a photosensitizer called Indocyanine Green. He ended up doing 40 days of treatment. His protocol included:

  • Chemotherapy
  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Nebulization therapies
  • Hyperthermia
  • Intramuscular injections
  • Non-invasive detox therapies
  • Repurposed medications
Tests
Natera Signatera
Outcome

Peter’s Signatera tests, which analyze ctDNA, improved, meaning there was a dramatic reduction in tumor burden.

Holly: 44-year-old with stage 1 breast cancer

Diagnosis

Holly is a 44-year-old woman who first visited Infuze MD in 2023, seeking to detoxify her body due to abnormal levels of heavy metals in her blood. More than a year later, in late 2024, she was diagnosed with stage 1 invasive ductal carcinoma after finding a lump in a routine check-up with her gynecologist. A biopsy and an MRI were performed. She talked to us and expressed wanting to do conjunctive cancer treatment at Infuze MD.

Treatment

Holly did a 5-week program; her therapies included:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Nebulization therapies
  • Hyperthermia
  • Intramuscular injections
  • Non-invasive detox therapies
Tests
Natera Signatera
Outcome

Holly is currently in remission, as her Signatera tests have come back negative, meaning they could not detect circulating tumor DNA.

Mia: 45-year-old with stage 4 stomach cancer

Diagnosis

Mia, a 45-year-old woman, was diagnosed with Stage 4 gastric cancer in late 2024. She was first misdiagnosed with severe gastritis earlier in the year. She also suffered from anemia as a symptom of her cancer. She was recommended chemotherapy and did a few rounds; however, her body was deteriorating, and she experienced harsh side effects from the chemotherapy. She came to us wanting to do integrative cancer treatments, while working with a holistic nutritionist.

Treatment

Mia did a 5-week program; her therapies included:

  • Chemotherapy
  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Peptides
  • Nebulization therapies
  • Hyperthermia
  • Non-invasive detox therapies
  • Specialized supplements
Tests
Natera Signatera
Outcome

By the conclusion of her program, Mia went into complete remission! Unfortunately, while travelling abroad, she became lax with her supplements and nutrition plan and tested positive again for ctDNA. This highlights cancer’s tendency to recur, which is why attacking cancer cells from all fronts on an ongoing basis is necessary to make a full recovery. She began becoming aggressive with all the recommendations Dr. Abellera had and her tumor markers began going down again. 

Claudia: 38-year-old with mold exposure, heavy metal toxicity, and autoimmune issues

Diagnosis

Claudia, a 38-year-old woman, was diagnosed with mold illness toxicity and heavy metals in her system, on top of an autoimmune disease diagnosis. She was experiencing severe brain fog, fatigue, IBS, and other symptoms. She came to see us in late 2024, wanting to improve her health and alleviate life-altering symptoms.

Treatment
  • Pro-oxidant therapies
  • Red light therapy
  • Chiropractic care
  • Non-invasive detox therapies
  • Diet changes
  • Custom supplements
Tests
Initial mycotoxins test
Most recent MARCoNS test
Outcome

Her most recent MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci), which is an antibiotic-resistant staph that resides deep in the nasal passage, came back negative after being positive. She was also tested for yeast and fungus for one month, and the results came back negative.

Brandon: 74-year-old with stage 4 metastatic lung cancer

Diagnosis

Brandon is a 74-year-old man who was diagnosed with stage 4 non-small cell lung cancer (NSCLC) in 2021. He had a previous prostate cancer diagnosis in 2019, which was managed with surgery. He did immunotherapy and it helped momentarily, but he began to deteriorate and opted for conjunctive cancer care, combining traditional cancer therapies with alternative treatments.

Treatment

Brandon continues to do treatments as part of his maintenance; his treatment plan has included:

  • Chemotherapy
  • Pro-oxidant therapies
  • Alkalinization therapies
  • Peptides
  • Non-invasive detox therapies
Tests
Lumera Xpanded Profile
Outcome

At present, Brandon has no new sites of disease and is going very well clinically. He still continues to come in twice per month for pro-oxidant therapies.

Zack: 55-year-old with metastatic pancreatic cancer

Diagnosis

Zack, a 55-year-old man, was diagnosed with stage 4 pancreatic cancer with metastasis and lymph node involvement. He did chemotherapy and targeted radiation therapy, and had surgery. He lost 11 kg due to his cancer, and his cancer expanded after his original diagnosis in early 2023. He came to Infuze MD wanting to extend his life and alleviate symptoms.

Treatment

Zack’s treatment protocol at Infuze MD includes:

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Peptides
  • Nebulization therapies
  • Intramuscular injections
  • Non-invasive detox therapies
  • Specialized supplements
  • Chiropractic care
Tests
Natera Signatera
Outcome

Zack was only given 2 months to live when he was diagnosed; he still has cancer but is alive more than a year and a half later, and doing better.

Jenna: 50-year-old with papillary thyroid cancer with lymph node involvement

Diagnosis

Jenna, a 50-year-old woman, was diagnosed with papillary thyroid cancer in August of 2024 after a Prenuvo scan in January of 2024 had shown a nodule on her thyroid. She had two surgeries, one to remove the right lobe of the thyroid and two lymph nodes, and another to remove additional lymph nodes after confirming mutation. She was later recommended a full thyroidectomy, but she didn’t pursue it. BRAF mutation showed positive BRAF V600E IHC, which means the cancer is aggressive and has high risk of recurrence. She came in seeking help in managing her cancer and her hypothyroidism. A MycoTOX test was performed to rule out mold exposure. Her organic acids test did show deficiencies and imbalances.

Treatment

Jenna did 4 weeks of treatment, her therapies included: 

  • Mitochondrial support therapies
  • Pro-oxidant therapies
  • Intramuscular injections
  • Non-toxic detox therapies
  • Red light therapy
  • Specialized supplements
Tests
Initial biopsy
Latest Natera Signatera
Outcome

Jenna has consistently tested negative for ctDNA trough Natera Signatera tests. She is currently receiving high-dose vitamin C therapy and HBOT for maintenance.

MycoTOX profile:

Indicates a high concentration of ochratoxin A (OTA). Ochratoxin A is one of the most abundant food-contaminating mycotoxins. It is also a frequent contaminant of water-damaged houses and of heating ducts.

Guardant Reveal ctDNA test: Did not reveal circulating tumor DNA.

Tests

Initial Signatera test: Shows a positive result for circulating tumor DNA.

Most recent Signatera test: Came back negative for ctDNA. The Spike in April is due to the patient having to temporarily discontinue all therapies and supplements for the RGCC Onconomics test to determine which chemotherapy drug would be appropriate for her.

Tests

Initial Natera test: Her test on May 08, 2025, shows 76.44 MTM/mL.

  • Latest Natera test: Still shows circulating tumor DNA, but it has decreased.
Tests

Natera Signatera: Did not detect ctDNA.

Tests

Natera Signatera: His Signatera tests show a decrease in ctDNA molecules per mL of plasma over time.

Tests

Most recent Signatera results: No ctDNA detected.

Tests

Natera Signatera history: In late 2024, during therapy, and in early 2025, Mia’s tests were negative for ctDNA. Her cancer has recurred, but it’s being managed.

 

Tests

Initial mycotoxins test: Showed elevated results for fumonisins b3 (FB3), a mycotoxin produced by a fungus usually found in cereals and cereal-based foods, and can be carcinogenic.

Most recent MARCoNS test: Negative results.

Tests

Lumera Xpanded Profile: Identifies therapeutic guidance considerations and confirms immunotherapy eligibility.

Tests

CA 19-9 test: This test measures the amount of a protein called CA 19-9 in the blood. It’s often used to monitor pancreatic cancer. Zack’s CA-19 in early 2024 was high.

Tests

Initial biopsy: She was diagnosed with metastatic papillary thyroid cancer.

Tests
  • Latest Natera Signatera: Shows negative results for circulating tumor DNA.
Skip to content